Effect of Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Levels of inflammatory marker
研究概览
简要总结
This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.
详细描述
Chronic kidney disease (CKD) is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals.
The diagnosis of CKD is established by laboratory testing, most often by estimating glomerular filtration rate (GFR) from a filtration marker, such as serum creatinine or cystatin C, using various formulas, or by testing urine for albumin or protein (or both).
Pentoxifylline (PTX), a synthetic dimethylxanthine derivative used initially to treat intermittent claudication in patients with peripheral arterial disease due to its hemorheological effects, has been shown to have potent antioxidant, anti-inflammatory, antidiabetic, anti-cellular-damage, and antifibrotic effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ˃ 18 years old.
- •Both sexes.
- •Patients with chronic kidney disease (CKD) stages G3, G
- •Patients with proteinuria < 1 g.
排除标准
- •Patients who are terminally ill.
- •Patients with Diabetes mellitus.
- •Patients with proteinuria > 1 g.
- •Patients with a history of hemodialysis.
- •Patients with active infection or hospitalized.
- •Patients with recent cerebral and /or retinal Hemorrhage.
- •Patients taking warfarin or theophylline-containing drugs.
- •women who are taking oral contraceptives, pregnant, or lactating
- •Patients with a history of adverse reactions to Pentoxifylline.
- •Patients with polycystic kidney disease.
- •Patients with obstructive uropathy.
研究组 & 干预措施
Group 1
Patients received the standard therapy. The routine standard consisted of angiotensin-converting enzyme inhibitors (ACEI) (Ramipril 1.25 mg), a calcium-based phosphate binder (calcium acetate 700 mg, containing 180 mg of calcium), alfacalcidol (0.25 µg), antihypertensive medications, and diuretics.
干预措施: Angiotensin-converting enzyme inhibitors (Ramipril) (Drug)
Group 2
Patients received one capsule of Pentoxifylline 400 mg twice daily for 6 months, in addition to their standard therapy.
干预措施: Pentoxifylline (Drug)
结局指标
主要结局
Levels of inflammatory marker
时间窗: 3 months post-procedure
Levels of inflammatory marker was recorded.
次要结局
未报告次要终点
研究者
Ashraf Hassan
Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, Cairo, Egypt.
Ain Shams University